Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
Even geduld...

Nieuws over “Biotechnologie”

15:00 · Co-Diagnostics Announces Reverse Stock Split · Persbericht

15:00 · Co-Diagnostics Announces Reverse Stock Split · Persbericht

13:00 · Evogene Announces Appointment of Dr. Olga Nissan as its Vice President of Business Development · Persbericht

03:40 · QURE Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm · Persbericht

29/12 · 10x Genomics to Present at the 44th Annual J.P. Morgan Healthcare Conference · Persbericht

29/12 · Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies · Persbericht

24/12 · Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline · Persbericht

23/12 · QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm · Persbericht

23/12 · Bio-Techne to Present at the 2026 J.P. Morgan Healthcare Conference · Persbericht

22/12 · Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy · Persbericht

22/12 · The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS · Persbericht

22/12 · Kazia Therapeutics Regains Full Nasdaq Listing Compliance · Persbericht

22/12 · PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan · Persbericht

19/12 · PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

19/12 · AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS · Persbericht

19/12 · BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook · Persbericht

19/12 · BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook · Persbericht

19/12 · Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030 · Persbericht

19/12 · Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

18/12 · Galapagos Announces Topline Results from Two Phase 3-Enabling Studies with Selective TYK2 Inhibitor GLPG3667 in Dermatomyositis and Systemic Lupus Erythematosus · Persbericht

18/12 · Galapagos maakt topline resultaten bekend van twee fase 3-enabling studies met selectieve TYK2-remmer GLPG3667 bij dermatomyositis en systemische lupus erythematodes · Persbericht

Mijn selecties